Daily Anesthesiology Research Analysis
Analyzed 23 papers and selected 3 impactful papers.
Summary
Today’s top anesthesiology-related research spans translational cardioprotection, perioperative immunomodulation, and mechanistic management of opioid-induced pruritus. Human cardiac tissue data implicate caveolin-3 downregulation in ischemia–reperfusion injury, a meta-analysis supports preoperative recombinant IL-2 to prevent postoperative immunosuppression, and a preclinical study identifies NR2B/PKC/CaMK II signaling as a target to reduce intrathecal morphine-induced pruritus without impairing analgesia.
Research Themes
- Translational cardioprotection in cardiac surgery
- Perioperative immunomodulation
- Mechanisms and management of opioid-induced pruritus
Selected Articles
1. Caveolin-3 serves as a therapeutic target for myocardial ischemia-reperfusion injury in cardiac surgery patients.
Human atrial samples collected before ischemia and 30 minutes after reperfusion showed approximately 60% reduction in caveolin-3, accompanied by downregulation of pro-survival kinases and upregulation of pro-apoptotic markers. The magnitude of Cav3 loss correlated with biochemical injury and cardiomyocyte death, suggesting Cav3 as a translational target to mitigate perioperative myocardial I/R injury.
Impact: This is direct human evidence linking Cav3 downregulation to myocardial injury and signaling changes during cardiac surgery. It bridges robust mechanistic findings from animal models to human tissue, highlighting a potentially druggable target.
Clinical Implications: Perioperative strategies that preserve or restore Cav3 expression/function may reduce myocardial injury in cardiac surgery. The findings support biomarker development and rationale for interventional trials targeting Cav3-associated pathways.
Key Findings
- Caveolin-3 protein levels decreased by approximately 60% after reperfusion in human atrial tissue.
- Phosphorylation of ERK1/2, Akt, STAT3, and GSK3β was markedly downregulated after I/R.
- Pro-apoptotic markers Bax and caspase-3 increased, while anti-apoptotic Bcl-2 decreased.
- Cav3 reduction correlated negatively with myocardial injury and cardiomyocyte death markers.
Methodological Strengths
- Paired human tissue sampling pre-ischemia and post-reperfusion enabling within-subject comparisons
- Multi-modal assessment (western blot, immunofluorescence, apoptosis staining) with correlation to clinical biomarkers
Limitations
- Observational, correlative design without interventional manipulation of Cav3
- Sample size and patient heterogeneity not detailed; atrial tissue may not fully represent ventricular myocardium
Future Directions: Evaluate pharmacologic or gene therapy approaches to modulate Cav3 perioperatively, define causal mechanisms, and test impacts on clinical endpoints (enzymes, infarct surrogates, outcomes) in randomized trials.
BACKGROUND: Caveolin-3 (Cav3) has been reported to protect both normal and failing hearts against myocardial ischemia/reperfusion (I/R) injury in rodent models. However, there is currently no evidence demonstrating its cardioprotective effects in human hearts. In this study, we investigate whether Cav3 is involved in myocardial I/R injury during cardiac surgery and the underlying mechanisms. METHODS: Human atrial tissues were collected from cardiac surgery patients before myocardial ischemia and 30 min after reperfusion. The tissue samples were analyzed by western blot to assess the expression levels of Cav3, pro-survival kinases, and apoptosis-related proteins. Immunofluorescence assessed Cav3 distribution, and apoptosis staining evaluated cardiomyocyte death. Cardiac enzymes, lactate levels, and hospitalization data were also recorded. RESULTS: The expression levels of cardiac Cav3 protein exhibit around 60% reduction following myocardial I/R injury in the human heart. The reduction of Cav3 showed a strong negative correlation with cardiac injury. Similarly, the phosphorylation of ERK1/2, Akt, STAT3, and GSK3β, is markedly downregulated in cardiac tissue following I/R injury. Furthermore, the pro-apoptotic protein Bax and caspase-3 shows substantial upregulation, while the anti-apoptotic protein Bcl-2 is significantly downregulated. Importantly, a strong positive correlation was observed between decreased Cav3 expression and reduced phosphorylation of survival kinases, while a negative correlation was found with the extent of myocardial injury and cardiomyocyte death. CONCLUSION: Our data suggest that the downregulation of caveolin-3 is associated with increased cardiac injury in the human heart. Targeting Cav3 may represent a promising therapeutic strategy for mitigating myocardial I/R injury in patients undergoing cardiac surgery.
2. Effects of preoperative recombinant Interleukin 2-based immunomodulation on outcome after gastrointestinal cancer surgery: a systematic review and meta-analysis.
Across 13 randomized trials (n=504), preoperative subcutaneous rIL-2 prevented postoperative immunosuppression, including maintenance of lymphocyte metrics, with no signal for severe adverse events. The analysis synthesized decades of trials and evaluated dosing strategies relevant to perioperative care.
Impact: This PRISMA-style synthesis of RCTs supports a perioperative immunomodulatory approach to reduce immune suppression after cancer surgery, a key driver of infectious complications.
Clinical Implications: rIL-2 could be considered for evaluation in modern perioperative protocols to reduce immune dysfunction; however, larger trials focusing on clinical endpoints (infection, complications, mortality) and optimal dosing are needed before routine adoption.
Key Findings
- Thirteen RCTs (total n=504) were included after screening 2,324 records.
- Preoperative rIL-2 prevented postoperative immunosuppression, maintaining lymphocyte-related metrics.
- Severe adverse events did not appear to be a relevant concern across included trials.
Methodological Strengths
- Systematic search across multiple databases with RCT-only inclusion
- Meta-analytic synthesis evaluating preoperative dosing strategies and immune outcomes
Limitations
- Cumulative sample size remains modest (n=504) across decades of trials
- Heterogeneity in dosing regimens and outcome measures; limited reporting of hard clinical outcomes
Future Directions: Conduct adequately powered multicenter RCTs to define optimal dosing and quantify effects on clinical endpoints (infection rates, complications, length of stay), and evaluate interactions with modern ERAS and oncologic therapies.
BACKGROUND: Patients undergoing gastrointestinal cancer surgery are often immunocompromised and susceptible to infectious complications. Recombinant Interleukin 2 activates effector immune cells and stimulates the expansion of regulatory T-cells, making it a promising intervention for prevention of inflammatory complications. OBJECTIVE: Our objective was to investigate effects of different preoperative rIL2 dosages on postoperative outcome parameters. METHODS: We conducted a systematic literature review and meta-analysis and included RCTs that recruited adult patients undergoing gastrointestinal cancer surgery who received preoperative subcutaneous rIL2. We performed a systematic search of MEDLINE (via PubMed), Web of Science and the Cochrane Central Register of Controlled Trials (CENTRAL) from 1989 up to April 18th, 2024. RESULTS: Out of 2324 screened studies, we included 13 RCTs with a total of 504 patients. Lymphocyte counts [cells/mm CONCLUSION: Preoperative rIL2-based immunomodulation prevents postoperative immunosuppression while the occurrence of severe side effects does not seem to be relevant.
3. Xiaofeng Granules alleviate intrathecal morphine-induced pruritus via inhibiting the NR2B/PKC/CAMK II signaling pathway.
In a mouse model, oral Xiaofeng Granules significantly reduced scratching induced by intrathecal morphine while preserving analgesic efficacy. XF inhibited phosphorylation of NR2B, PKC, and CaMK II in spinal dorsal horn tissue; this effect was reversed by intrathecal NMDA, implicating the NMDA–NR2B/PKC/CaMK II pathway.
Impact: Identifies a mechanistic pathway for managing a common anesthetic adverse effect (intrathecal morphine-induced pruritus) without compromising analgesia.
Clinical Implications: While preclinical, these data support targeting NMDA–NR2B/PKC/CaMK II signaling to mitigate neuraxial opioid-induced pruritus and motivate development of mechanism-based adjuvants.
Key Findings
- Xiaofeng Granules reduced intrathecal morphine-induced scratching in mice without diminishing analgesic efficacy (tail-flick metrics maintained).
- XF inhibited phosphorylation of NR2B, PKC, and CaMK II in the spinal dorsal horn after morphine administration.
- The antipruritic effect of XF was reversed by intrathecal NMDA, implicating NMDA–NR2B/PKC/CaMK II signaling.
Methodological Strengths
- Combined behavioral (scratching counts) and analgesic assays (tail immersion) to separate antipruritic from antinociceptive effects
- Molecular validation via western blot with pathway reversal using NMDA
Limitations
- Preclinical mouse study; generalizability to humans is uncertain
- Compound herbal formulation limits identification of active constituents and dose standardization
Future Directions: Isolate active components of XF, define dose–response and safety, and test mechanism-based adjuvants targeting NR2B/PKC/CaMK II in early-phase clinical trials for neuraxial opioid-induced pruritus.
PURPOSE: The administration of intrathecal morphine frequently induces pruritus as an adverse reaction. Xiaofeng Granules (XF) is a compound preparation improved from the ancient formula "Xiaofeng Powder". It has been proven to relieve skin itching caused by various reasons in clinical practice. The aim of the study was to evaluate the effect of XF on pruritus caused by intrathecal morphine and possible mechanism. METHODS: Male C57BL/6 mice were intrathecally injected with morphine to induce scratching behavior. The effects of XF on intrathecal morphine-induced pruritus and analgesia were evaluated. The number of scratching response was counted within 30 min after morphine injection. The warm-water tail immersion test was conducted to measure the tail flick latency (TFL) within 120 min after morphine injection. The maximum possible effect percentage (%MPE) and area under the curve (AUC) were calculated based on TFL to evaluate the analgesic effect. Western blot was performed to evaluate the phosphorylation levels of NR2B, PKC and CAMK II in the dorsal horn of the lumbar spinal cord of mice. RESULTS: Compared with control treatment, intrathecal morphine elicited obvious scratching response when providing analgesic effect in a dose dependent manner. Gavage administration of XF can significantly reduce intrathecal morphine-induced scratching behavior without affecting its analgesic efficiency; besides, XF can inhibit the phosphorylation of NR2B, PKC, and CAMK II induced by intrathecal morphine, which can be reversed by intrathecal injection of NMDA. CONCLUSIONS: XF can relieve intrathecal morphine-induced pruritus and may be related to the inhibition of the NR2B/PKC/CAMK II signaling pathway.